Alessio Cortellini, Consultant Medical Oncologist and Assistant Professor at Campus Bio-Medico University of Rome, shared a post on X:
“First-line EGFR + NSCLC is rapidly evolving with more effective systemic strategies.
But is there a ‘third way’ of intensification? In our meta-analysis just published in JTO and JTO CRR, integrating LAT with EGFR TKIs significantly improved PFS and OS with acceptable safety.
Upfront integration in 1L may be where LAT expresses its full potential.
Grateful to all co-authors and especially Leonardo Brunetti for leading this effort.”
Title: First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
Authors: Leonardo Brunetti, Giacomo Colella, Giuseppina Rita Di Fazio, Giulia La Cava, Valentina Santo, Federica Pecci, Jiulia Rotow, Jessica R. Bauman, Amin H. Nassar, Elio Adib, Abdul Rafeh Naqash, Marco Tagliamento, Roberto Ferrara, Fabrizio Citarella, Marco Russano, Biagio Ricciuti, Corinne Faivre-Finn, Lizza E. L. Hendriks, Antonio Passaro, Bruno Vincenzi, Fabian Acker, Lisa Derosa, David Planchard, Hugo J. W. L. Aerts, Silvia Novello, Francesco Passiglia, Carlo Greco, Sara Ramella, Alessio
Other Articles Featuring Alessio Cortellini on OncoDaily.